guid move focu cash deploy
view see beat temper legaci product
drive beat soft guid togeth upcom season
headwind anticip share may range-bound lead
increas investor focu cash deploy remain sector perform
strong beat diminish somewhat legaci product
sensipar neulasta drive beat combin
beat light/conserv guidanc revenu
declin bare straddl consensu high end see
first blush sever one-tim product revenu benefit recogn
could detract excit around otherwis
impress quarterli beat especi relat growth product
aimovig conjunct light top bottom-lin guid
repeat expect management/cav season
impacts/weak anticip potenti share weak range-
bind could increas attention/pressur mobil
cash reserv substanti increas buyback
pursu increas remain board-approv
share repurchas may inspir confid continu abil
grow bottom-lin despit guidanc larg consensu
vs st remain sector perform rate given challeng
associ potenti execut see immedi market
interest detail note investor slide
call unexpectedli call enbrel one brand
longer period patent protect franchis increas financi
invest initi struck us surpris given mark
sinc fda initi approv on-going enbrel ip litig vs
sandoz howev followup call management suggest high sustain
convict protect ip aimovig benefit
one-tim account pull-though tailwind even back
one-tim item launch continu impress us neulasta
beat vs st yr/yr sale growth benefit
singl purchas announc move forward
biosimilar soliri program conced
yet enrol patient patient screen on-going
valu usd unless otherwis note
price prior trade day market close estimate unless otherwis note
see limit forward growth emerg
pipelin yet fill shoe amgn matur product
eros see inexpens biotech compani
rel basi like dividend perspect
steadi cash flow despit headwind base busi
despit see risk amgn recent near-
term product launch cgrp humira biosimilar
upsid slower product eros remain
sidelin
biosimilar remain major part valuationw see
amgn intern pipelin biosimilar major revenu
ep driver though remain slightli cautiou
street launch time view recent setback
humira biosimilar indic challeng launch
environ initi anticip model amgn
biosimilar launch remicad rituxan avastin
herceptin humira see launch ahead
upsid model
launch repatha upcom
focu emerg pipelin becom construct
launch
omecamtiv parsabiv key driver off-set base busi
eros see repatha uptak signific driver
close monitor rx share follow posit long-
risk greater-than-expect competit core
busi franchis lower-than-expect uptak
grow busi develop regulatori setback
bloomberg capit market estim upside/downside/target
valu dcf basi use wacc
termin growth rate view
trade appropri valu forward price-to-earnings basi vs
peer similar growth prospect discount project
revenu market product contribut
sh discount risk-adjust revenu pipelin product
contribut revenu contribut cash
contribut result price target
support sector perform rate
upsid scenario assum longer-than-
expect delay entranc biosimilar
market slower-than-expect revenu eros
base busi higher-than-expect uptak repatha
downsid scenario assum faster-than-
expect market entri biosimilar lead greater
market share eros price pressur
base busi regulatory/litig setback
biosimilar franchis continu slow uptak repatha
aimovig launch continu impress despit one-tim tailwind
detract optic aimovig report sale doubl consensu estim
quarter vs st still see quarter exclud one time item
impress note initi first blush potenti blue-ski commerci revenu
extrapol erron base averag cumul weekli script vs cumul
patient start script point modest though still impress
annual run rate base respect quarter end script week
holiday quarter-end cumul patient assum best-cas discontinu
lower repatha estim full impact lower price competit rebat effect
updat market model fulli incorpor impact recent
decreas repatha list price announc octob see note full transit
lower list price take time fulli impact averag price launch transit
late bid cycl part commerci formulari last year end
unit sold lower list price medicar live
cover date model gradual decreas list price q/q basi
achiev full coverag lower price also model lower
gross-to-net discount increas market penetr out-year
addit increas estim rebat substanti reduc repatha peak us/ww
sale estim vs previou estim
model chang updat model reflect neg impact repatha
competit price cut rebat increas enbrel estim reflect
surprisingli resili price/volum impact substanti increas prolia estim
reflect continu volum growth trend signific room growth
franchis global increas expens estim particularli sg reflect
sustain legaci franchis invest commerci neurolog oper
compani report capit market estim
chang model revenu expens mm expens mm expens mm incom mm incom mm incom mm non-gaap ep
compani report capit market estim
incom product total product product product cost expens non oper incom ebit non tax tax net ep ep
compani report capit market estim
discount rate equiti growth rate mm except per-shar data discount add add effect add termin
compani report capit market estim
valu dcf basi use wacc termin growth rate
view trade appropri valu forward price-to-earnings basi vs peer
similar growth prospect discount project revenu market product
contribut discount risk-adjust revenu pipelin product contribut
revenu contribut cash contribut result
sh price target support sector perform rate
risk rate price target
factor neg influenc valuat rate greater-than-expect
competit core busi franchis lower-than-expect uptak
grow busi develop regulatori setback late-stag pipelin
global biotechnolog compani focus develop manufactur
commerci novel biotherapeut primarili cancer nephrolog inflammatori
diseas cardiovascular diseas bone diseas pioneer use
recombin dna produc world success blockbust biotech drug
compani core busi erythropoietin epo stimul agent esa
epogen aranesp neutrophil stimul neulasta franchis
obtain princip inflammatori diseas busi enbrel acquisit
immunex go forward compani primari futur growth driver repatha
